Phase

Related by string. phase * * Phase III clinical trials . Phase III trials . Phase III clinical . Phase II . Phase III . Phase Forward . pivotal Phase III . Phase IIb clinical . Phase 2b clinical . ongoing Phase 1b . ongoing Phase IIIb . knockout phase . pivotal Phase . Phase IV . Phase IIb . initiate Phase . Phase IIa . randomized Phase . Phase 2a . Phase 2b . Phase IIb trial . Phase 1b *

Related by context. All words. (Click for frequent words.) 84 Phase II 77 Phase III 71 Phase 1a 70 Phase 1b 69 pivotal Phase 69 placebo controlled Phase 68 Phase 2a 68 multicenter Phase 67 phase IIb 66 dose escalation Phase 66 Phase 2b 66 Phase Ib 66 initiate Phase 66 Phase IIb 66 randomized Phase 66 Phases II 65 Initiated Phase 65 phase Ib 65 pivotal Phase III 65 Phase 2a clinical 64 Phases 64 phase IIa 64 Phase IV 64 Phase III clinical 64 phase 63 Phase 2b trial 63 Phase Ib clinical 63 dose escalation trial 63 phase IIa clinical 63 Phase IIa 63 Phase IIa clinical 63 Initiate Phase 62 randomized controlled Phase 62 Phase Ia 62 Pivotal Phase 61 Phase IIB 61 AZX# Phase 61 Phase 1b clinical 61 Phase 2b clinical 60 Phase Ib II 60 GALNS 60 phase 2a 60 Phase 2b study 60 Phase IIb clinical 60 Randomized Phase 60 Phase 2a trial 60 multicenter phase 59 LUX Lung 59 Phase IIb trial 59 multicenter randomized Phase 59 Phase1 59 dose escalation clinical 59 Phase 1a clinical 59 Phase IIa trials 59 confirmatory Phase 59 Phase Ib study 59 dose escalation study 58 Phase IIb trials 58 Phase IIa trial 58 IIa clinical 58 TMC# [002] 58 Phase IIIb clinical 58 multiple ascending dose 57 confirmatory Phase 3 57 Initiates Phase 57 Phase IIIb 57 HCV SPRINT 57 Phase III clinical trials 57 Phase #b/#a 57 IIa trial 57 confirmatory Phase III 57 treatment naive genotype 57 dose escalation 57 BRIM2 57 Phase III Pivotal 56 APEX PD 56 Phase III pivotal 56 Phase 1b trial 56 phase IIb clinical 56 Phase III trials 56 multicenter Phase II 56 Commences Phase 56 BRIM3 56 Successfully Completes Phase 56 Phase 2a clinical trials 56 Phase III confirmatory 56 R#/MEM # 56 phase Ib clinical 56 registrational trial 55 Testosterone MDTS ® 55 Phase 2b clinical trials 55 IMPACT IMmunotherapy 55 Exherin TM 55 PRECiSE 55 treatment naïve genotype 55 Phase lll 55 Pivotal Trials 55 GLP toxicology studies 55 dependent kinase inhibitor 55 Scopus Affiliation Identifier 55 lorcaserin Phase 55 clinical trial 55 Phase IIa proof 55 Commence Phase 55 LymphoStat B Phase 54 IMPACT DCM 54 blinded randomized placebo controlled 54 placebo controlled 54 PSMA ADC 54 CONSERV 54 Phase IIA 54 ascending dose 54 IMC #B 54 alvespimycin 54 Phase 1b clinical trials 54 Phase IIb clinical trials 54 ongoing Phase 1b 54 dose cohort 54 immunosuppressive compound 54 Phase 2b monotherapy 54 IND enabling 54 APF# Phase 54 single ascending dose 54 Zerenex 54 Second Pivotal Phase 54 drug pipeline TAFA# 54 MEND CABG 54 label multicenter Phase 54 Multiple Ascending Dose 54 REG2 54 evaluating mipomersen 54 registrational 54 Albuferon Phase 54 Phase Ib clinical trials 54 pharmacokinetic PK study 54 IIa trials 54 Confirmatory Phase 54 Fast Tracked Phase 53 dosing cohort 53 Phase IIa clinical trials 53 randomized Phase 2b 53 Phase IIIB 53 Pivotal Phase III 53 dosing cohorts 53 VICTOR E1 53 SUCCEED trial 53 MEND CABG II 53 torezolid phosphate 53 multicenter randomized placebo controlled 53 Phase III psoriasis 53 PRE SURGE 53 Phase IIb Trial 53 Randomized Phase II 53 HuMax EGFr 53 multicenter dose escalation 53 JZP 53 European Sepsis Trial 53 pivotal bioequivalence 53 Dacogen injection 53 initiate Phase Ib 52 double blinded placebo 52 ADVANCE PD 52 pharmacodynamic PD 52 LUMINATE 52 IIb clinical trial 52 initiate Phase IIb 52 IIa clinical trial 52 multicentre phase 52 Phase #b/#a trial 52 Phase 2a proof 52 LUVENIQ 52 Phase 1b Clinical Trial 52 randomized Phase IIb 52 farletuzumab 52 JunJing II 52 initiate multicenter 52 ALN VSP Phase 52 randomized multicenter 52 IIa clinical trials 52 IND submission 52 Advaxis Phase 52 ARDIS 52 JAK inhibitor 52 SAGD Phase 52 initiate Phase 2b 52 L BLP# 52 initiated Phase Ib 52 Phase #b/#a clinical 52 preclinical 52 JunJing II Phase 52 AIMM trial 52 PHASE 52 phase IIb III 52 Phase III Clinical Trials 52 DURATION 52 Luveniq 52 Cloretazine R VNP#M 52 huC# DM4 52 phase IIb trial 52 II Clinical Trial 52 Phase III Clinical Trial 52 cannabinor 52 Phase #/#a 52 placebo controlled Phase III 52 hGH CTP Phase 52 TASKi2 52 Archexin 51 randomized placebo controlled 51 EOquin 51 Phase 1b dose escalation 51 clinical trials Multikine 51 INCB# [001] 51 Phase IIb III 51 IMGN# 51 pharmacokinetic PK 51 ACCLAIM COPD 51 IMA# 51 Phase 2b Clinical Trial 51 adecatumumab MT# 51 oral prodrug 51 Fx #A 51 label dose escalation 51 ASA# 51 rALLy clinical trial 51 IDX# 51 TKB# 51 preclinical toxicology 51 fidaxomicin Phase 51 multicenter Phase III 51 LibiGel Phase III 51 confirmatory pivotal 51 ILLUMINATE 51 Pivotal Trial 51 blinatumomab 51 Prostate AdenoCarcinoma Treatment 51 lintuzumab 51 Pivotal Study 51 systemic Phase 1b 51 TMC# C# 51 BLA submission 51 tolevamer 51 celgosivir 51 BCX# 51 oral sapacitabine 51 Randomized phase 51 multicenter randomized double 51 STEALTH C 51 double blind placebo 51 dose cohorts 51 MKC# MT 51 Plicera 51 AP# [003] 51 CDAD Clostridium difficile 51 relapsed refractory multiple myeloma 51 NHDP phase 51 Amigal 51 Phase III randomized controlled 51 oral ridaforolimus 51 PEG Interferon lambda 50 Phase III placebo controlled 50 EOquin TM 50 investigational protease inhibitor 50 Bayer HealthCare Onyx Pharmaceuticals 50 PFO migraine 50 OPT CHF 50 randomized multicentre 50 including eniluracil ADH 50 Goldcrest Dreams 50 RIBBON 50 PXD# 50 Clinical Trial 50 aclidinium bromide 50 examining REOLYSIN 50 M Vax 50 Phase III multicenter 50 denosumab oncology 50 Genz # 50 Phase III HEAT 50 Allovectin 7 50 GetGoal Phase III 50 RDEA# 50 multicenter randomized controlled 50 masked placebo controlled 50 pharmacokinetic studies 50 label multicenter 50 Pre RELAX AHF 50 NP2 Enkephalin 50 Sapacitabine 50 tramiprosate Alzhemed TM 50 PEG PAL 50 Tesetaxel 50 trodusquemine 50 Phase IIb Clinical Trial 50 Fibrillex TM 50 ORMD 50 REOLYSIN ® 50 fostamatinib 50 AeroLEF TM 50 Trial Evaluating 50 Pivotal Phase II 50 trastuzumab DM1 T DM1 50 BiovaxID Phase 50 pharmacokinetics PK 50 ATTRACT 50 opioid induced bowel dysfunction 50 glufosfamide 50 trastuzumab DM1 50 blind randomized placebo 50 methylnaltrexone 50 Urocidin 50 mertansine 50 Efficacy Trial 50 deforolimus 50 bapineuzumab AAB 50 Phase 2b kidney transplant 50 DermaVir Patch 50 Phase 2b randomized 50 rindopepimut 50 Elagolix 50 randomized double 50 initiate multicenter Phase 50 PANVAC VF 50 CR# vcMMAE 50 Panzem R NCD 50 NHDP Phase 50 multicentre randomized 50 Phase Ib IIa 50 PrevOnco ™ 50 R roscovitine CDK cyclin 50 CAMMS# 50 Huaiyin Power Plant 50 Initiates Phase II 50 initiate Phase 1b 50 Biglow Canyon Phase 50 generation PNP inhibitor 50 comparing alemtuzumab 50 NJ1 49 initiate Phase IIa 49 randomized controlled multicenter 49 Zerenex Phase 49 oral treprostinil 49 generation URAT1 inhibitor 49 ofatumumab 49 PF # [001] 49 placebo controlled clinical 49 bardoxolone 49 huN# DM1 49 Pralatrexate 49 antibody MAb 49 ENDEAVOR IV 49 dose escalation phase 49 XL# [003] 49 thorough QT 49 MOTIVATE 49 FORTIS M trial 49 Dose Ranging Study 49 CB2 selective receptor agonist 49 satraplatin Phase 49 Solorel 49 MLN# 49 Phase III registrational 49 IIa Clinical Trial 49 NO# [002] 49 under NHDP Phase 49 selectin antagonist 49 IMC A# 49 PI3K/Akt pathway inhibitor 49 elotuzumab 49 PRX # 49 ascending doses 49 TLK# 49 Hyphanox 49 randomized Phase III 49 Ozarelix 49 Phase III VISTA 49 Androxal TM 49 Zenvia Phase III 49 BLA filing 49 AERAS-#/Crucell Ad# 49 Luramist TM 49 preclinical efficacy 49 mGluR5 NAM 49 Biopharmaceuticals AG 49 SinuNase TM 49 REVIVE TA 49 OvaRex R 49 Daclizumab 49 KRN# 49 HGS ETR1 49 Study Evaluating 49 HepeX B TM 49 Phase III Psoriasis 49 HCD# [002] 49 BiTE antibody MT# 49 seliciclib CYC# 49 Phase III Trial 49 clinical trials 49 lead Aganocide compound 49 cetrorelix pamoate 49 trastuzumab emtansine T DM1 49 T DM1 49 phase IIIb 49 COSIRA trial 49 obatoclax 49 FORTIS M 49 evaluating RDEA# 49 Bezielle 49 RSD# oral 49 midstage trials 49 HDAC Inhibitor 49 Flutiform ™ 49 oral deforolimus 49 Phase IIb kidney transplant 49 Liraglutide Effect 49 Capesaris 49 randomized controlled 49 Thorough QT 49 Pimavanserin 49 CEQ# 49 CRLX# 49 Testosterone MDTS R 49 dacetuzumab SGN 49 registrational Phase 49 Randomised 49 Sapacitabine CYC# cell 49 PREOS R 49 AQ4N 49 D#B 49 PDE4 inhibitor 49 HEPLISAV ™ 49 REVIVE Diabetes 49 multicentre 49 Clinical Trial Evaluating 49 Phase III randomized 49 TASQ 49 LBH# 48 QLT# 48 MAP# 48 dose dose escalation 48 telaprevir dosing 48 Cloretazine ® 48 AVADO 48 controlled multicenter Phase 48 oral COTI 48 Ispinesib SB # 48 PDX pralatrexate 48 PS# DARA 48 budesonide foam 48 ZALBIN dosed 48 Phase 2b Trial 48 phase IIb study 48 RECORD1 48 OncoVEX GM CSF 48 pharmacokinetic 48 TBC# 48 assessing T DM1 48 Phase 2a preventative 48 BIIB# 48 Completes Patient Enrollment 48 docetaxel Taxotere R 48 randomized multicenter trial 48 CLIRS 48 Phase III Trials 48 AEG# 48 LymphoStat B TM 48 HCV RESPOND 2 48 ALD# 48 Forodesine 48 preclinical pharmacokinetic 48 OXi# 48 Fodosine 48 Diamyd ® 48 ARIES 48 OvaRex ® MAb 48 Cytokinetics Incorporated NASDAQ CYTK 48 ENRICH trial 48 peginesatide 48 imetelstat GRN#L 48 XL# SAR# 48 SYMMETRY trial 48 ENGAGE AF TIMI 48 NEVO RES 48 unblinding 48 anti CTLA 48 hypoxia activated prodrug 48 #DF [001] 48 ACCLAIM II 48 HspE7 48 ozarelix 48 RE SURGE 48 Carb Controller 48 rALLy trial 48 safety tolerability 48 CLIRS trial 48 mipomersen 48 TRC# 48 APPRAISE 48 ZYBRESTAT fosbretabulin 48 velafermin 48 Eniluracil 48 Protease Inhibitor 48 Pharmacokinetic PK 48 Acetavance TM intravenous acetaminophen 48 Investigational Device Exemption IDE 48 Spiegelmer ® 48 Aflibercept 48 tezampanel NGX# 48 Prodarsan 48 PLK1 SNALP 48 label multicenter randomized 48 blinded randomized 48 OLpur TM H2H 48 SPIRIT FIRST 48 ALSYMPCA 48 PRIMO CABG 48 orally dosed 48 riociguat 48 midstage clinical 48 Truvada tablets 48 HuMax CD# 48 Clinical Study 48 GOUT 48 ACC5 Phase 48 avanafil PDE5 inhibitor 48 PF # [002] 48 Initiates Clinical 48 VALOR trial 48 forodesine 48 Traficet EN 48 randomized discontinuation trial 48 albiglutide 48 TACI Ig 48 pharmacodynamic 48 dyskinesia PD LID 48 OHR/AVR# 48 multicenter randomized 47 RG# [001] 47 Quinamed 47 NSABP B 47 Dose Escalation Study 47 velafermin belinostat 47 Sorafenib HCC Assessment 47 double blinded randomized 47 BEMA Buprenorphine 47 PSN# [002] 47 AKT inhibitor 47 MAA submission 47 ganetespib 47 BENLYSTA ™ 47 Neo Bladder Augment 47 Syncria albiglutide 47 Phase IIa Clinical Trial 47 selective androgen receptor modulator 47 budesonide MMX 47 EPC# 47 ATTAIN 47 NOX E# 47 MGCD# [001] 47 generation purine nucleoside 47 NOR Flash NAND Flash 47 VEGF Trap 47 Pharmos pipeline 47 Qnexa TM 47 RESTORE CLI trial 47 tanespimycin 47 Ostarine 47 MIST II 47 PTH analogue 47 mGluR5 negative 47 prospective randomized placebo 47 SAR# [002] 47 Phase 2a Clinical Trial 47 Phenoptin 47 Voclosporin 47 subcutaneous Herceptin 47 combination REOLYSIN 47 lorvotuzumab mertansine 47 Exelixis XL# 47 ZACTIMA 47 FOLOTYN ® 47 Genasense oblimersen sodium Injection 47 Oral NKTR 47 placebo controlled randomized 47 designated HVTN 47 Sym# 47 metastatic hormone refractory 47 AeroLEF 47 Ngezi Phase 47 multicentre randomized double 47 Ophena TM 47 TG MV 47 JunJing III 47 liposomal formulation 47 MOZOBIL 47 PRESEPT 47 PROTECT AF 47 ocrelizumab 47 NDA submission 47 Phase #/#a trial 47 Dose Escalation 47 Oglemilast 47 non nucleoside HCV 47 CCR5 mAb 47 elacytarabine 47 leading oral taxane 47 EQUATE OB 47 BENLYSTA ® 47 CUSTOM III 47 rhIGFBP 3 47 Proxinium TM 47 PC DAC Exendin 47 Contrast Echocardiography 47 Saforis 47 randomized #:#:# 47 IMPACT DCM clinical 47 Guanilib 47 Trastuzumab DM1 47 alogliptin 47 BiTE R 47 Achieves Primary Endpoint 47 Lock Loop PLL 47 isavuconazole 47 GRNVAC1 47 Matrix Phase 2b 47 labial herpes 47 Anturol TM 47 Alocrest 47 LCP AtorFen 47 COMFORT II 47 palifosfamide Zymafos TM 47 Cohort 47 enzastaurin 47 gemcitabine Gemzar ® 47 EGS# 47 Xcellerated T Cells 47 randomized discontinuation 47 viral kinetic 47 teduglutide 47 Imvamune R 47 Mtsare Khevi Field 47 ASONEP 47 compound INCB# 47 KSP inhibitor 47 unique alkylating agent 47 Dose escalation 47 axitinib 47 Feasibility Trial 47 ZFP Therapeutic 47 SBIR Phase 47 unresectable stage 47 perifosine KRX 47 Phase 2a Trial 47 ACCEDE 47 ZYBRESTAT TM 47 sodium thiosulfate STS 47 confirmatory 47 Tawke # 47 TEMSO 47 Vitaxin 47 ATL# [001] 47 TELCYTA 47 Proellex TM 47 Actilon 47 PEG SN# 47 Aplidin R 47 Amrubicin 47 First Patient Dosed 47 AIR CF2 47 Metastatic Melanoma 47 investigational humanized monoclonal antibody 47 Alpharadin 47 XL# XL# XL# 47 CORLUX 47 Paradox Basin # 47 Azedra 47 TAXUS IV 47 Aryplase 47 inhaled AAT 47 fidaxomicin Phase 3 47 LymphoStat B belimumab 47 multicenter 47 BrachySil 47 resource delineation 47 EDEMA4 47 TG# [001] 47 Talotrexin 47 AMPAKINE CX# 47 OncoGel 47 Ofatumumab 47 Tolerability Study 47 Jumonville # 47 Lovaxin C 47 IND Investigational New 47 Investigational 47 opioid bowel dysfunction 47 Aplidin 47 candidates Dyloject TM 47 bavituximab monotherapy trial 47 EndoTAG 47 next generation URAT1 47 investigational pan BCR 47 dexpramipexole 47 unblinded 47 KNS # 47 ONCONASE R 47 JAK1 47 evaluable patients 47 Restanza 47 Telatinib 47 Randomized Controlled 47 ELACYT 47 pharmacodynamic effects 47 cancer neuroendocrine tumor 47 NGX# 47 eculizumab 47 drug conjugate 46 PRT# 46 bortezomib Velcade 46 Phase IIb IIIa 46 oral taxane 46 Hypoactive Sexual Desire Disorder 46 Aclidinium 46 Mipomersen 46 Multicenter Randomized 46 SparVax TM 46 LB# [003] 46 DSMB recommended 46 dose limiting toxicities 46 Vicriviroc 46 efficacy endpoint 46 NEO3 46 multicenter clinical 46 BLOOM DM 46 TOLAMBA 46 INFORM 46 BrachySil TM 46 Subphase 46 CF# [002] 46 voreloxin 46 ALISTA TM 46 fosbretabulin 46 Population Enumeration 46 sapacitabine 46 TAXUS ATLAS 46 Indibulin 46 Hedgehog pathway inhibitor 46 AIR CF3 46 HCV Genotype 46 orally bioavailable 46 FDA Investigational Device 46 #:# randomization 46 sequential dose escalation 46 Zensana TM 46 PEGylated interferon 46 Tarceva TM 46 oral calcitonin 46 ABSORB trial 46 Trofex 46 ACHIEVE 46 BR.# 46 Parkinson disease levodopa induced 46 ularitide 46 tremelimumab 46 Combination REOLYSIN R 46 sunitinib malate 46 LibiGel testosterone gel 46 Atu# 46 nab paclitaxel 46 stated Michelle Berrey 46 PRECISE Trial 46 MVax 46 Harry Palmin President 46 recurrent glioma 46 OMS# 46 GetGoal 46 Human Coagulation Factor 46 TransMID 46 laquinimod 46 EOquin TM phase 46 oral RELISTOR 46 Ocrelizumab 46 Phase IIb dose 46 Chidliak exploration 46 Corlux 46 DEB# 46 receptor tyrosine kinase inhibitor 46 avanafil 46 blind randomized 46 tesetaxel 46 lintuzumab SGN 46 EXPLORE Xa 46 Completes Enrollment 46 Nuvion 46 Prefeasibility 46 prospective multicenter 46 TASKi3 46 GVAX R 46 Investigational Device Exemption 46 dextromethorphan quinidine 46 confirmatory clinical 46 evaluating Xcytrin 46 Efficacy Results 46 ARRY # 46 Curaxin CBLC# 46 omacetaxine mepesuccinate 46 tesmilifene 46 brentuximab vedotin SGN 46 Glufosfamide 46 Allovectin 7 R 46 CATIE AD 46 Enobia 46 PROSTVAC TM 46 romidepsin novel 46 PRX# 46 ChronVac C ® 46 pafuramidine 46 solithromycin 46 initiated confirmatory Phase 46 CTA# Injection 46 candidate Liposomal Grb 46 UVIDEM 46 neratinib 46 refractory CLL 46 generation calcineurin inhibitor 46 trial evaluating Prochymal 46 Zemiva ™ 46 custirsen 46 tosedostat 46 AzaSite Plus 46 STTR Phase 46 novel histone deacetylase 46 mg/m2 cohort 46 CLL SLL 46 IIIA NSCLC 46 Phase 2a Study 46 perifosine 46 methionine aminopeptidase 46 subcutaneous methylnaltrexone 46 Pharmacokinetic Study 46 BLOOM Behavioral modification 46 cathepsin K inhibitor 46 ADXS# 46 controlled multicenter 46 resource delineation drilling 46 biliary tract cancer 46 CHAMPION PCI 46 Gabapentin GR 46 Annamycin 46 transmucosal delivery system 46 BIBW 46 CRMD# 46 occlusion PAO 46 Charles L. Dimmler 46 includes TOLAMBA TM 46 ruxolitinib 46 Feasibility Study 46 drug NP2 Enkephalin 46 pramlintide metreleptin 46 Benlysta belimumab 46 volociximab 46 PrevOnco 46 ADMIRE HF 46 Phase #/#a clinical 46 PROVENGE ® 46 tolerated dose MTD 46 StemEx 46 mitogen activated ERK kinase 46 blinded placebo controlled 46 stage IIIB 46 Blind Placebo Controlled Trial 46 VEGFR2 inhibitor 46 PREGNANT PROCHIEVE Extending GestatioN 46 R#/MEM 46 Special Protocol Assessment 46 ZYBRESTAT 46 generation MEK inhibitor 46 recombinant PSMA vaccine 46 Enzastaurin 46 Alzhemed TM 46 CG# oncolytic virus 46 GRN#L 46 randomized controlled clinical 46 ENACT 46 Clinical Trial Results 46 HuMax CD4 46 Prodarsan ® 46 QNEXA ® 46 Pinglu Project 46 Biologics License Application 46 Medidur TM FA 46 catheter occlusion CO 46 Novolimus 46 Neuvenge 46 INCB# [002] 46 Phase Ia Ib 46 tgAAC# 46 cilengitide 46 Meets Primary Endpoint 46 GV# [001] 46 relapsing multiple sclerosis 46 cetrorelix 46 ThGRF 46 FAME Study 46 RELOVAIR ™ 46 INSPIRE Trial Phase III 46 Augment Injectable 46 Multicenter Phase 46 placebo controlled dose escalation 46 Dextofisopam 46 Zemplar Capsules 46 Costayaco 46 APTIVUS 46 ORAL Solo 46 CRx 46 Zybrestat 46 visilizumab 46 metastatic castrate resistant 46 Levacor 46 urocortin 2 46 Allovectin 7 ® 46 PEG IFN 46 Abong gold 46 vidofludimus 46 Omigard 46 omiganan 46 PS# [001] 46 oral picoplatin 46 Degarelix 46 ToGA 46 MoxDuo ® 46 LUNESTA TM 46 studies evaluating satraplatin 46 DDP# 46 Dyloject TM 46 ILUVIEN ® 46 GATTEX ® 46 ENDEAVOR IV clinical 45 Atiprimod 45 STRIDE PD 45 R roscovitine 45 evaluating tesamorelin 45 prospective randomized multicenter 45 RhuDex 45 MINDSET 45 Rigel R# 45 EndoTAG TM -1 45 RhuDex ® 45 oral methylnaltrexone 45 Ceflatonin R 45 eniluracil 45 Phase III TRIST 45 RiVax 45 platinum refractory 45 SNT MC# 45 ritonavir boosted danoprevir 45 MAGE A3 ASCI 45 MDV# 45 microdosing studies 45 metastatic sarcomas 45 Apaziquone 45 RADIANT 45 clinical trials SGN 45 Denufosol 45 baminercept 45 Darusentan 45 multicenter placebo controlled 45 velaglucerase alfa 45 evaluating Prochymal 45 romidepsin 45 prospective multicenter randomized 45 Phase 2b Study 45 Tyrima 45 COSTAR II 45 Cetrorelix 45 RSD# 45 nitric oxide donating prostaglandin 45 TRACON Pharmaceuticals Inc. 45 ABL inhibitor 45 PRTX 45 maximally tolerated dose 45 Phase Ib Clinical Trial 45 pegloticase 45 EmbraceAC 45 VTEM airborne surveys 45 telomerase therapeutic 45 evaluating bafetinib 45 humanized monoclonal antibody 45 Synavive 45 MKC# 45 Alequel ™ 45 eliglustat tartrate 45 GSK# [001] 45 MEK inhibitor RDEA# 45 TELINTRA R 45 SAR# [004] 45 MERLIN TIMI 45 frac horizontal 45 ISIS # 45 AIR CF1

Back to home page